Clinical Trial Update: Safety and Efficacy Study of CC312 for Moderate to Severe SLE [Phase 1]

View source ↗

Summary

Clinical trial update for a Phase 1 safety and efficacy study of CC312 in moderate to severe systemic lupus erythematosus, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CC312 (CC312)

Snippet

Sponsor: CytoCares Inc | Conditions: SLE - Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING